147497-57-2

Basic information

• Product Name: 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene
• Synonyms: 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene;4-(Bromomethyl)-4'-fluoro-1,1'-biphenyl
• CAS NO: 147497-57-2
• Molecular Formula: C₁₃H₁₀BrF
• Molecular Weight: 265.1209032
• Mol File: 147497-57-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 331.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene(147497-57-2)
• EPA Substance Registry System: 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene(147497-57-2)

Safety Data

• Hazardous Substances Data: 147497-57-2(Hazardous Substances Data)

Usage

General Description

1-[4-(Bromomethyl)phenyl]-4-fluorobenzene is a chemical compound with the molecular formula C14H11BrF. It is a derivative of benzene and consists of a phenyl group with a bromomethyl substituent and a fluorine atom attached to the benzene ring. 1-[4-(broMoMethyl)phenyl]-4-fluorobenzene is often used in organic synthesis and pharmaceutical research due to its unique structural properties and potential for various chemical reactions. It is important to handle this chemical with care due to its potentially hazardous properties and to follow all safety protocols when working with it in a laboratory setting.

Upstream product

• 147497-56-1 (4'-Fluoro-biphenyl-4-yl)-methanol 
• 873-75-6 4-bromobenzenemethanol 
• 5720-05-8 4-methylphenylboronic acid 
• 1765-93-1 4-fluoroboronic acid 
• 106-38-7 para-bromotoluene 
• 72093-43-7 4-methyl-4'-fluorobiphenyl 
• 460-00-4 1-Bromo-4-fluorobenzene 

Downstream Products

• 352665-57-7 3-(4'-fluoro-biphenyl-4-ylmethyl)-2-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester 
• 147497-60-7 α-[2-(4'-fluoro-4-biphenylylmethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yloxy]-acetaldehyde 
• 1124219-53-9 N-{3-[(4'-fluoro-1,1'-biphenyl-4-yl)methoxy]phenyl}piperidine-4-carboxamide hydrochloride 
• 1277100-02-3 N-{3-[(4'-fluoro-1,1'-biphenyl-4-yl)methoxy]phenyl}-1-(1-methylethyl)piperidine-4-carboxamide hydrochloride 
• 1277239-96-9 C₂₈H₃₁FN₂O₂ 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION

Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.

Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia

The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies in achieving high selectivity for one isoform over the other. The therapy of certain diseases, such as acute myeloid leukemia (AML), may require α-isoform specific targeting. The s

4-AZAINDOLE DERIVATIVES

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.